Technetium-99 metastable nuclide(
99mTc), a daughter nuclide of
99Mo, is a radio-isotope essential to the diagnosis of the disease like cancer. However, in Japan, a total amount of
99Mo for pharmaceutical ingredient of
99mTc is imported from abroad. Especially all of the
99Mo in Japan has been imported and it accounts for about 14% of all of the
99Mo production doses in the world. It is an urgent issue to secure domestic
99Mo supply for stable delivery to patients.
Presently the materials testing reactor JMTR of Japan Atomic Energy Agency(JAEA) has been refurbished and will be restarted after long shutdown since 2007. Considering the above context, JAEA has investigated a feasibility to apply the neutron activation method, so-called the (n, γ) method, to
99Mo production with JMTR. The (n, γ) method is low cost because of no need for treating the irradiated nuclear fuel. Here the results of the investigation in collaboration with the industries and universities are described. The amount of 37TBq(1000Ci)/week of
99Mo is assumed as an appropriate amount of
99Mo for the domestic supply. Also a concentration of
99mTc is practically needed up to 37GBq/mL or more for drug preparation. As a result, it was found to solve the problem of low specific activity of
99Mo in the Mo target that high efficient
99Mo adsorbents and high concentration techniques of
99mTc are required.
View full abstract